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Abstract 
 
Individuals aged >65 years are the fastest expanding population demographic 
throughout the developed world.  Consequently, more aged patients are 
receiving diagnoses of impaired renal function and ‘nephrosclerosis’ - age 
associated histological changes in the kidneys.   Recent studies have shown 
that the aged kidney undergoes a range of structural changes and has altered 
transcriptomic, haemodynamic and physiologic behaviour at rest and in 
response to renal insults.  These changes impair the ability of the kidney to 
withstand and recover from injury, contributing to the high susceptibility of the 
aged population to acute kidney injury, and their increased propensity to 
develop subsequent progressive chronic kidney disease.  This review 
examines these features of the aged kidney, and explores the various proven 
and putative pathways contributing to the changes seen with aging in both 
experimental animal models and in man.  The potential for further study to 
increase understanding of the aged kidney, and to lead to novel therapeutic 
strategies is discussed.  
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Introduction 
 
The Centre for Disease Control predicts that 72 million Americans will be 
aged 65 years or older by 2030, accounting for approximately 20% of the U.S. 
population.1 Eurostat predicts that 28% of Europeans will be aged over 65 by 
2060.2 These increasing numbers of elderly individuals will inevitably lead to 
increasing diagnoses of age related kidney impairment. 
 
In renal aging a complex interplay of genetics, environmental change and 
cellular dysfunction leads to characteristic structural and functional changes.3 
This review summarises our current understanding of the factors driving age-
associated changes in the kidney. 
 
Clinical features of renal aging in man 
 
Structural changes of aging 
With age there is a decline in total nephron size and number, tubulointerstitial 
changes, glomerular basement membrane thickening and increased 
glomerulosclerosis (Figure 1).4,5  This age-related histological appearance is 
frequently described as “nephrosclerosis” and describes a combination of 2 or 
more histological features: any global glomerulosclerosis, tubular atrophy, 
interstitial fibrosis > 5% and any arteriosclerosis. A study of healthy kidney 
donors demonstrated nephrosclerosis in only 2.7% of biopsies from donors 
aged less than 30 years, 58% from 60-69 year olds and 73% from donors 
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aged greater than 70.6 Cadaver studies estimate that the upper limit of normal 
glomerulosclerosis in aging exceeds 10%.7 
 
Nephrosclerosis remains a poorly understood observation, and its importance 
within an aging kidney is far from clear. We know that nephrosclerosis 
correlates with aging and mild hypertension in healthy living donor kidneys.8 
Importantly however, age related decline in measured GFR does not correlate 
with the presence or absence of nephrosclerosis.9 In fact, nephrosclerosis 
does not correlated with urine albumin excretion, family history of end-stage 
renal disease, body mass index, serum cholesterol, glucose, or uric acid.10 It 
remains unclear then, whether nephrosclerotic changes have any contribution 
to the functional changes seen in aging, or are perhaps distinct and 
unrelated.11  
 
The Aging-CKD spectrum 
Our understanding of the pathways underlying renal aging is incomplete and 
derived from studies of healthy aging kidneys and extrapolation from 
experimental and clinical studies of CKD.  
 
It is important to note the distinction between these conditions, with the 
mechanisms of progressive genetic, immune or toxin mediated injury seen in 
CKD distinct from the gradual, prevalent changes seen in the aging kidney.  
Throughout this review we will focus on the changes seen in the ‘healthy’ 
aged kidney, though due to the paucity of experimental and clinical data 
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available in aging kidneys at times reference will be made to mechanisms in 
progressive CKD which may also be of relevance to the uninjured but aged 
kidney.  Processes discussed below such as cellular senescence, fibrosis, 
vascular rarefaction and glomerular loss are common to both aging and CKD 
despite differences in causation and natural history.  Similarities are also seen 
in the behaviour of the chronically damaged and the aged kidney including 
their heightened susceptibility to further injury and deficient repair.13   
 
Declining Glomerular Filtration Rate (GFR) 
Population GFR declines with age with longitudinal studies differing in their 
reported rates of decline.14,15 While the MDRD study suggested renal function 
declined at a rate of 3.8ml/min/year/1.73m2, rates as low as 0.4 
ml/min/year/1.73m2 in the Netherlands have been described.16–19 A Japanese 
cohort study suggests the rate of GFR decline increases with advancing 
age.20 
 
Studies of robustly phenotyped Kuna Indians with minimal prevalence of 
hypertension and cardiovascular disease demonstrate comparable declines in 
renal function over time, suggesting that there is a true age related decline, 
rather than the cumulative effects of cardiovascular disease.21 How a 
significant minority of individuals apparently remain free of nephrosclerosis 
and GFR loss remains poorly understood and merits further study. 
 
 
 
	 6	
Decreased Tubular Function 
Aging is characterised by progressive tubular dysfunction, decreased sodium 
reabsorption, potassium excretion and urine concentrating capacity potentially 
contributing to an increased susceptibility to AKI.22–24 Elderly patients 
demonstrate decreased trans-tubular potassium gradients and fail to increase 
distal tubule potassium excretion when hyperkalaemic or in response to 
fludrocortisone.25 Decreased potassium excretion correlates with decreasing 
GFR, and may reflect a degree of reduced sodium and chloride delivery to the 
distal convoluted tubule.26 
 
Vascular Changes  
There are important changes to blood vessel structure and function in the 
aging kidney. There is increased extracellular matrix (ECM) deposition, 
increased intimal cell proliferation in pre-glomerular arterioles and increased 
intrarenal shunting and capillary bypassing predominantly affecting the 
cortex.27 
 
Increased renal sympathetic tone increases vasoconstriction whilst aortic 
baroreceptor attenuation of sympathetic tone decreases with age.28,29  Renal 
vasodilators such as atrial natriuretic peptide, nitric oxide (NO) and amino 
acids become less effective.30–32 Human studies demonstrate decreased NO 
production and platelet responsiveness,33 with accumulation of the NO 
synthase inhibitor asymmetric dimethylarginine in elderly individuals.34 In 
particular, aging males become increasingly NO dependent to maintain renal 
plasma flow.35 
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Biological Processes and Mediators Implicated in Experimental Aging  
 
Most rodent experimental models of renal disease are undertaken in young 
animals, potentially affecting their relevance to the aging kidney. There is 
limited or no data available regarding the response of the aged rodent kidney 
to experimental glomerulonephritis, AKI, ureteric obstruction, diabetic 
nephropathy, 5/6th nephrectomy, adriamycin nephropathy or renal 
transplantation.  Some aspects of renal aging may be studied in vitro but 
others require study in vivo in aged mice or other experimental animals (Table 
1). 
 
Studies have demonstrated increased susceptibility of the aged kidney to 
ischemia reperfusion injury (IRI) or toxic AKI.36,37 Aged mice exhibit increased 
mortality, AKI severity and chemokine/cytokine responses in a model of 
uterine sepsis.38 Furthermore, aged mice exhibited increased mortality, 
prolonged injury, reduced regeneration, increased scarring and microvascular 
rarefaction following renal IRI compared to young mice.39 
 
The biology of aging is complex involving diverse changes to cells, tissues, 
organs and the surrounding microenvironment (Figure 2). Many of these 
processes and mediators are discussed below but the reader should 
appreciate that this list is not exhaustive.    
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A) Signalling pathways and oxidative stress in the aging kidney 
 
Falling Klotho levels 
Klotho is a transmembrane protein strongly expressed in the kidney and a co-
receptor for fibroblast growth factor-23 (FGF-23). Whilst its exact physiological 
role in aging remains incompletely understood Klotho has a role in modulating 
diverse aging associated pathways. These include calcium and phosphate 
metabolism with implications for vascular calcification, hypoxia, cellular 
regeneration and senescence. Indeed, homozygous transgenic Klotho 
knockout mice demonstrate arteriosclerosis and vascular changes as part of 
their aging phenotype.40 Similarly, FGF-23 knockout mice display high serum 
phosphate and increased renal phosphate reabsorption in addition to their 
aging like phenotypes.41,42 It may be that these vascular changes contribute 
directly to the aging phenotype we observe.  
 
Klotho’s effects on tissue function, autophagy and fibrosis could contribute to 
abnormal healing and possibly nephrosclerosis.43,44 Importantly, Klotho 
deficient mice exhibit reduced lifespan, skin and muscle atrophy, osteoporosis 
and ectopic calcification.45 Conversely, mice overexpressing Klotho have a 
longer mean lifespan.43   
 
Klotho decreases epithelial senescence in response to oxidative stress, 
reduces binding of nuclear factor kappa-B (NFκB) and increases cell survival 
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in experimental uremia.46 Klotho also represses insulin and insulin-like growth 
factor 1 (IGF1) signalling, likely contributing to reduced oxidative stress in 
mice and in vitro models employing Klotho overexpression.43,45,47  Importantly, 
Klotho supplementation in a rat UUO model attenuated renal fibrosis.48   
 
Increasing Wnt Activation 
Mechanisms for the anti-fibrotic effects of Klotho include suppression of 
fibroblast growth factor and modulation of Wnt signalling.49–51 Wnt is a 
conserved signalling pathway activated post injury which promotes pro-fibrotic 
gene expression.52 As Klotho levels fall during aging Wnt signalling increases 
promoting fibrosis and vascular calcification53 though further experiments are 
required to clarify causality.  Wnt activation promotes renal fibrosis in murine 
models and is a target for inhibition54,55 with antagonism of Wnt and its 
downstream targets ameliorating experimental renal fibrosis.56,57  The 
interplay between potentially causative pathways is illustrated by studies 
demonstrating that renin-angiotensin-aldosterone signalling is Wnt mediated 
with experimental blockade protecting mice from post-injury fibrosis and 
proteinuria.58   
 
Declining Peroxisome Proliferator-activated Receptor gamma (PPARγ) 
levels 
PPARγ is a nuclear receptor whose activity decreases with age in 
experimental rodent models, whilst PPARγ agonists increase Klotho 
expression.59,60 The PPARγ pathway protects against oxidative stress and 
improves vascular function in vitro and in aging rats61–63 with PPARγ agonists 
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protecting human fibroblasts against features of aging and oxidative stress in 
vitro.64 PPARγ agonism by pioglitazone or baicalin improves age related 
vascular oxidative stress or renal inflammation respectively, providing a 
potential therapeutic strategy for elderly patients with reduced PPARγ 
activity.60,65 
 
Angiotensin II 
Angiotensin II (AT2) is increased in aged rats compared to young controls,66 
driving increased fibrosis, glomerular cell growth and ECM accumulation,67 
altered mitochondrial redox function and cytoplasmic oxidative stress in the 
aging kidney.66,68,69  Angiotensin I receptor activation simulates the pro-fibrotic 
β-catenin/Wnt pathway mentioned above.70  Treating aging rats with captopril 
reduces TGF-β activity and attenuates renal fibrosis.71,72 AT2 antagonism via 
ACEi/ARB improves mitochondrial number and function in rats and further 
studies are warranted.73   
 
Oxidative Stress 
A balance exists in tissues between reactive oxygen species(ROS) generation 
and oxidant scavenging and defence mechanisms. When this balance is 
disturbed, either by increased generation of ROS, decreased detoxification or 
both, then oxidative stress may occur. It has been hypothesised that oxidative 
stress leads to tissue damage and contributes to the aging phenotype. 
Certainly, there is evidence in murine and human studies, of both increased 
ROS generation and altered oxidant removal in aging.74–76 
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There is a continuous generation of oxidative species through various 
mechanisms, including mitochondrial oxidative phosphorylation, which 
increases within the aging kidney.76,77Studies in aged rat kidneys support the 
theory there is also reduced oxidant defence demonstrating decreased 
antioxidative capacity and reduced levels of Cu/Zn-SOD, catalase and GSH 
reductase.78,79 This overall increased oxidative load may contribute to chronic 
cellular stress and mitochondrial injury77 as well as apoptosis and possibly 
inducing tubular cell damage.80,81  
 
Contributing to this increased oxidative stress, it has been noted that sirtuins 
(important antioxidant molecules) are diminished with age. Sirtuins protect 
against renal inflammation, fibrosis and apoptosis while improving 
autophagy.82,83 Thus, defective ability to respond to cell stress in aged kidneys 
may contribute to the aged phenotype.84 Mouse models of reduced SIRT-1 
expression demonstrate increased apoptosis and fibrosis following UUO.85 
Additional Sirtuin functions include histone deacetylation and regulation of 
transcription factors controlling cellular stress and survival.86,87 Altered Sirtuin 
levels in aging may contribute to aging phenotypes by altering the kidneys 
capacity to respond to oxidative stress and thus suffer increased oxidative 
DNA damage. 88,89 Interestingly, angiotensin-II (AT2) downregulates SIRT-3 in 
vitro, suggesting that the damaging effects of raised AT2 levels and low 
Sirtuin levels may be related in the aging kidney.90 
 
B) Cell cycle progression in the aged kidney 
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Aged animals have reduced proliferative responses after experimental IRI. 
Tubular epithelial cells in aged mice express higher levels of zinc-alpha (2)-
glycoprotein (AZGP1), limiting proliferation following IRI.91 Whilst reduced 
proliferation might be expected to delay recovery, AZGP1 knockout mice 
displayed worsened fibrosis after IRI with AZGP1 administration being 
protective, implicating control of proliferation as a mechanism limiting fibrosis 
with aging.92  Studies in several CKD models demonstrate G2/M arrest in 
tubular epithelial cells promotes renal fibrosis, but no studies have examined 
G2/M arrest in aging kidneys.93 
 
Cellular senescence, defined as a state of permanent cell cycle arrest, is a 
key anti-proliferative response to aging and injury. This crucial process shuts 
down damaged cells, protects against malignant transformation and limits 
excess fibrosis at both baseline and following injury.94 
 
Senescence may occur as a result of repeated cell division and telomere 
shortening (‘replicative senescence’) or following factors such as oxidative 
stress or genotoxic injury (‘stress induced premature senescence’ [SIPS]) 
(Figure 3).95 Increased numbers of senescent cells accumulate in multiple 
organs including the kidney with advancing age (identified by p16INK4a or 
senescence-associated β-galactosidase expression). 
 
Cell senescence limits fibroblast proliferation in tissue wounds however there 
is increasing interest in the role of the Senescence Associated Secretory 
Phenotype (SASP) in promoting fibrosis.94 SASP promotes fibrosis and organ 
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dysfunction in aging via release of factors including Interleukins-6 and 8, 
Wnt16B and GROα.96–98 Studies in murine renal transplantation showed that 
renal p16INK4a deletion reduced pathologic changes and interstitial fibrosis post 
ischemia reperfusion injury, supporting clinical findings that cellular 
senescence contributes to adverse long-term allograft outcomes.99  Cell 
stress is known to induce SIPS, and consistent with this porcine models have 
shown that renal p16INK4a expression increases after IRI.100  Interestingly, 
p16INK4a knockout mice exposed to experimental renal injury show improved 
recovery after IRI but worsened fibrosis after UUO.101,102  These superficially 
inconsistent findings may reflect the different pathological processes at play, 
with p16INK4a deficiency leading to less cell death and enhanced regenerative 
proliferation in AKI, but the lack of p16INK4a induced senescence inducing an 
exaggerated, maladaptive fibroblast response to ongoing injury in UUO. 
 
Recent seminal studies used transgenic animals to induce specific depletion 
of p16INK4a expressing senescent cells and demonstrated reduced markers of 
aging in multiple organs including the kidney and increased overall lifespan.103  
Other work has used Bcl2/xL inhibitors to deplete senescent cells in non-
transgenic animals.104  Whilst these findings open up exciting new therapeutic 
avenues for the selective targeting of senescent cells to prolong healthy 
lifespan, further studies focusing upon the aging kidney required. 
 
Telomere Shortening 
Telomeres are nucleotide sequences which act as a defensive “cap”: limiting 
activation of DNA repair pathways, protecting genetic material and minimising 
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background cellular stress response.105,106 Although telomere length declines 
with age, it remains controversial whether this is a primary process or a by-
product of aging.105,107 As telomeres shorten with aging and oxidative stress, 
chromosome instability ensues, leading to cellular instability, senescence and 
subsequent apoptosis.108 
 
Increased telomere shortening in telomerase deficient mice is associated with 
increased tubular injury and reduced tubular proliferation after renal IRI with 
reduced tubular cell autophagy implicated in the limited regenerative 
response.109,110 This implies a potential causal role for telomere shortening in 
some of the vulnerability of aging kidneys to injury and it is noteworthy that 
experimental elongation of shortened telomeres resulted in partial reversal of 
aged organ degeneration.111 
 
C)  Hypoxic Damage and Disordered Repair. 
Under physiological conditions, the kidney is supported by a network of 
resident mononuclear phagocytes and pericytes contributing to tissue 
homeostasis and vascular stability.  Renal oxygen delivery and the functional 
status of resident and recruited cells in the kidney have been shown to alter in 
aged and injured experimental animals. 
 
Hypoxia 
Whilst the healthy kidney has areas of low oxygen tension, reduced capillary 
density and increased hypoxia is recognised as a potential driver of CKD, and 
its role in normal aging is being explored. In experimental CKD, the expected 
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angiogenic response to hypoxia fails, instead resulting in fibrosis.112 Increased 
renal hypoxia has also been demonstrated throughout aged rat kidneys, most 
prominently in the cortical zones, as detected by use of the hypoxia sensitive 
marker pimonidazole.113 Aged rat kidneys demonstrate decreased VEGF 
globally and increased anti-angiogenic thrombospondin-1, resulting in 
capillary loss with increased glomerular sclerosis.114 Recently reported 
techniques to quantify subtle changes in the renal vasculature have potential 
to yield new information on the evolution of renal circulatory changes and 
hypoxia with advancing age.115  
 
Leukocytes 
Changes in leukocyte function promoting inflammatory activation occur with 
aging, though whether this is a cause or effect of aging remains unclear.116 
Increased inflammatory signalling and macrophage infiltration,117 with 
alterations in inflammasome components such as NOD-like receptor P3 
(NLRP3), NLRC4, pro-caspase-1, NFκB and cytokines including IL-1β and IL-
18 occur in aging.118 Aged murine macrophages demonstrate impaired 
autophagy and reduced nitrate release and phagocytosis.119 Healthy aged 
mice have increased glomerular macrophage numbers with increased 
macrophage infiltration evident post injury, with renal IRI models showing an 
increased influx of macrophage and T lymphocytes.39,120 Additionally, aged 
mice show defective upregulation of the cytoprotective enzyme 
hemoxygenase-1 after IRI, with pharmacological macrophage 
hemoxygenase-1 induction protecting against subsequent IRI.36 Finally, aged 
macrophages express reduced anti-inflammatory IL-10 during tissue repair in 
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non-renal injury models.121 Given the importance of IL-10, and the negative 
prognostic role of macrophage infiltrates in human renal disease, these aging-
associated changes potentially contribute to the increased rates of injury and 
maladaptive repair seen in aged kidneys.  
 
Further evidence for the importance of the aging immune system in renal 
aging comes from young-old bone marrow transplant (BMT) studies 
demonstrating that aged animals receiving BMTs from young mice exhibited 
reduced renal fibrosis and cellular senescence.122  
 
Pericytes  
Although important for microvascular health pericytes are also recognised as 
key cells in renal fibrosis.123,124 In aged mice renal pericytes decline in number 
and adopt a pro-fibrotic phenotype,125 implicating them in aging related fibrotic 
changes. Pericyte-endothelial detachment under pathological conditions and 
their differentiation into myofibroblasts promotes microvascular rarefaction, 
hypoxia and fibrosis.126,127 Proposed mediators of this pericyte-endothelial 
cross talk include VEGF and PDGF128 and blocking this pericyte-endothelial 
interaction attenuates microvascular damage and interstitial fibrosis.129,130  
 
Disordered Repair. 
The normal enzymatic equilibrium is disturbed in aging and the balance of 
metalloproteinases (MMP) shifts towards fibrosis potentially via upregulation 
of tissue inhibitor of metalloproteinase-1 and increased leukocyte 
recruitment,51 a pattern likely to result in increased collagen deposition.  
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Longitudinal studies of aging mice show increased Collagen I, III and TGF-
β151 whilst aging rat kidneys exhibit increased ECM deposition and TGF-β3 
expression and decreased MMP1 activity suggesting altered collagen 
production and processing.131 Further non-inflammatory pathways may 
contribute to histological changes seen, including pathways driven by Wnt and 
AT2 as mentioned.55 
 
The Aging Human Kidney 
The clinical implications of renal aging in man extend beyond changes in 
glomerular and tubular function. Although data generated by animal studies 
implicate multiple pathways of potential importance for human renal aging 
(Figure 4), data supporting their involvement in man is currently sparse, with 
further studies required.  
 
A) Signalling pathways and oxidative stress in the aging kidney 
 
Falling Klotho levels 
Klotho and FGF-23 are present in human kidneys.132 Klotho levels decline 
with age, and are implicated in accelerated age-related CKD and 
atherosclerosis.133,134 Conversely, patients with increased functional Klotho 
expression are reported to have increased lifespan.135 As Klotho falls, FGF-23 
levels increase, and alter phosphate and calcium homeostasis. Clinical 
studies in dialysis and CKD patients show that higher FGF-23 levels associate 
with increased mortality.136 
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Increasing Wnt activation 
Whilst direct evidence of Wnt activation in human aging is lacking, several 
Wnt antagonists are now undergoing Phase I clinical trials for cancer therapy 
in man.137 If effective, these agents offer new therapeutic options for aging 
associated or fibrotic renal disease. 
 
Declining PPARγ levels 
Agonists of PPARγ are used clinically as anti-diabetic agents. Retrospective 
reviews of renal outcomes in clinical practice suggest that augmented PPARγ 
activity opposes proteinuria in these patients.138 A meta-analysis of PPARγ 
use has also demonstrated that they associate with reduced rates of 
cerebrovascular disease, supporting a role in delaying age-associated 
pathology.139  There is a need for prospective trials assessing their effects on 
renal function. 
 
Angiotensin II 
Despite decreased plasma renin activity in the elderly serum angiotensin II 
levels do not fall and hypersensitivity to angiotensin II develops in the renal 
vasculature.140,141  Whilst ACEi and ARB drugs are in widespread use, there 
is a lack of human data on the impact of AT2 blocking treatments on normal 
renal aging and outcomes at present. 
 
Oxidative Stress 
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As discussed, oxidative stress represents a disruption of the balance of 
oxidant handling in tissues. In man longitudinal studies demonstrate increased 
oxidative stress in normal aging and CKD.74,142 Research has focused on 
advanced glycation end products as drivers of oxidative stress in aging. 
These molecules accumulate with age and are associated with increased 
arterial stiffness, inflammation, oxidative stress and declining renal function.143 
One pharmacological attempt to modify anti-oxidant status in patients with 
diabetic nephropathy showed no impact on proteinuria despite increased 
circulating antioxidant levels.144  Whether an alternative, longer term treatment 
approach in the healthy aged population might have efficacy remains 
untested. 
 
 
B) Cell cycle progression in the aged kidney 
The presence of increased numbers of senescent cells has been noted in 
chronic allograft nephropathy and have been proposed as drivers of the 
progressive fibrosis seen.145 Recent advances in our understanding of the 
roles of aging and stress in inducing the detrimental SASP phenotype adds to 
the importance of senescence cells found in both aged and disease affected 
human renal biopsies.146–148 In humans, senescence is maximal in the 
medulla, potentially reflecting increased oxidative and cellular stress and 
relative hypoxia resulting from the vascular changes discussed previously.149  
 
Telomeres 
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Telomeres shorten in human kidneys at a rate of 0.25% length per year.150 
While telomere shortening provides an elegant explanation of cellular aging, 
currently no data exists to link shorter telomeres to any histological or 
functional measure of renal aging.  Shorter telomeres associate with CKD and 
worse cardiovascular outcomes and are shorter in diabetic nephropathy 
where they associate with rates of disease progression.151,152 Furthermore, 
studies of hemodialysis patients show increased rates of telomere attrition 
suggesting they shorten in response to the physiological stress.153 Although 
intriguing, the importance of telomere shortening in human aging remains to 
be elucidated. 
 
C)  Hypoxia, inflammation and nephrosclerosis in the aged kidney 
Due to the inherent risks of renal biopsy, samples of healthy aged kidney are 
seldom available for assessment of levels of nephrosclerosis, and there are 
no time course studies available to chart the temporal relationships of the 
histological findings in the aged kidney. Ongoing progress in imaging 
technology should enable serial non-invasive assessment of renal perfusion, 
vascular resistance, hypoxia, inflammation and atrophy in healthy young and 
aged volunteers. 
 
Renal Hypoxia 
The clinical use of BOLD MRI imaging has demonstrated a lower pO2 in older 
kidneys compared to younger subjects.154 As intrarenal vascular disease 
contributes to increased glomerular sclerosis in aged biopsies it is possible 
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that subclinical disease leads to hypoxia before marked macroscopic changes 
occur.155 
 
Inflammation 
Inflammation is increased within the aging kidney in man, with pro-
inflammatory cytokines detectable in the serum correlating with age related 
renal disease.156,157 
 
Future Research 
Reviewing the current evidence base in clinical and experimental renal aging 
it is clear that more work is required to understand which pathways are 
dispensable and which represent ‘master regulators’ of the aging phenotype. 
Studies in aged animals should allow characterisation of both the importance 
and interdependence of factors predisposing aged kidneys to injury, fibrosis 
and maladaptive repair, with subsequent validation in man.  Due to the time 
and cost constraints inherent in using aged animals, establishing whether 
models of genetically accelerated aging such as the BubR1 progeroid mouse 
represent useful models of renal aging will be of value.158 BubR1 mice have a 
shortened lifespan and exhibit a variety of age related phenotypes, including 
sarcopenia, cataracts, fat loss, cardiac arrhythmias, arterial wall stiffening and 
impaired wound healing. Specific to kidney research, BubR1 deficient mice 
also demonstrate higher senescence-associated beta-galactosidase activity in 
kidney sections than aged matched controls.159 Whether they truly manifest a 
renal aging phenotype is yet to be determined. 
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Circulating factors 
Heterochronic parabiosis with aged and young mice sharing a common 
circulation has provided evidence in non-renal models that circulating factors 
may modulate features of aging including impaired regeneration and 
increased fibrosis.160–162 Proposed factors include β2-microglobulin and 
growth differentiation factor 11 and reversal of changes in the brain, cardiac 
and skeletal muscle has been shown.163–165 Debate continues as to the 
significance of individual factors.166–170 Whether such factors impact the 
function of the aged kidney remains completely unknown. 
 
Novel experimental species 
Undertaking studies of experimental renal disease in aged mice is challenging 
and other organisms may be of use.  Zebrafish have been used as a model 
for AKI and nephron regeneration and exhibit aging associated 
abnormalities.171–173 Thus the use of genetically manipulated zebrafish in 
renal aging studies may be informative. 
 
Novel therapeutic strategies  
Many pathways implicated in the aging process are the target of interventions 
to improve the aging phenotype in experimental mice (Figure 5).  Klotho 
agonists are under investigation via repurposing of established agents 
including PPARγ agonists, ACEI and ARB drugs.  The importance of 
maintaining a normal renal microvasculature and pericyte pool is increasingly 
understood174 and developing strategies to quantify microvascular function 
and to promote endothelial and pericyte health is a pressing clinical need.115  
	 23	
 
Drugs targeting cellular senescence (‘senolytics’) include siRNA therapies, the 
experimental agent navitoclax and the licenced drugs dasatinib and 
quercetin.175 In experiments these agents demonstrate selective toxicity to 
senescent cells, and their potential utility in animal models and man merits 
further study.  
 
Genetics 
Genome wide association studies (GWAS) have identified upregulation of 
several genes with aging. Whilst cumulative damage may well influence much 
of the elderly genetic milieu, candidate genes have declared themselves as 
being consistently highly expressed in aged kidneys.176–178 Despite the utility 
of GWAS in identifying disease specific pathways, it has proved difficult to 
discover any canonical aging pathways with GWAS.179  
 
The most promising genes encode for modulators of the glomerular filtration 
barrier, fibrosis and inflammatory mediators although difficulty arises when 
identified candidate genes do not match the experimental observations or 
models.180,181 Transcriptomic analysis identified 427 genes strongly 
associated with renal aging, including mortalin-2, a heat shock protein which 
may counteract cell senescence and IGF receptor, a target of Klotho.182–184 
 
GWAS remains however, a promising tool as whole genome analyses of 
GWAS data suggest that over 80 % of the heritability of aging is explained by 
common genetic variants.185 Future GWAS will continue to generate 
	 24	
meaningful results as more advanced statistical techniques develop, and 
researchers increase statistical power by increasing samples number, 
combining studies using meta-analytical techniques, multicentre 
collaborations and including more extreme phenotypes in the data.185–188 
 
Epigenetics 
Epigenetics is the study of genome changes that do not alter DNA sequence. 
Epigenetic changes in aging include methylation and deacetylation of histone 
lysine residues, chromatin changes and increased transcriptional noise.179,189 
Interestingly, similar changes in DNA methylation and histones are associated 
with CKD disease progression.190–192 The role of microRNA expression in 
modifying gene expression and nephrosclerosis is of interest,193  with data in 
other organs suggesting an influence on aging.194  
 
Conclusion 
Renal aging is complex and remains incompletely understood. Decreased 
protective factors, hypoxia and microenvironmental stress drive increasingly 
disordered inflammation and renal fibrosis. The resulting fibrosis, senescence 
and microvascular rarefaction exacerbate damage and promote progression. 
The future of treating renal aging likely lies in understanding the key initiating 
events and the common downstream pathways present in kidney aging that 
may be shared with CKD. This knowledge should allow the development of 
therapies capable of arresting the key mechanisms early to preserve kidney 
function throughout life. 
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Figure 1 -  Functional and structural changes in the aging kidney  
With increasing age there are alterations in the function of the kidney.  These 
are accompanied by both macroscopic and microscopic changes and result in 
an alteration in the response of the kidney to diverse insults. 
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Figure 2 – Alterations in cellular and physiological pathways in the 
aging kidney 
Diverse physiological, cellular and gene expression alterations occur in the 
aging kidney, impacting on homeostasis, function and the response to renal 
injury  
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Figure 3 - Cell cycle progression in the aged kidney   
Cell cycle arrest in G1/S phase becomes more prevalent with age and results 
in p16INK4a positive senescent cells expressing multiple cytokines promoting 
autocrine and paracrine changes in aged kidneys.  Whilst studies are lacking 
in aged animals, increased G2/M cell-cycle arrest in response to injury 
promotes maladaptive repair in murine kidney injury with raised G2/M counts 
correlating with fibrosis.93,195 G2/M cell-cycle arrest may have variable effects 
in different cell types, being profibrotic in renal tubular cells, but preventing 
intimal hyperplasia in young smooth muscle cells.196  
 
 
 
 
 
 
 
 
G1/S 
checkpoint 
S checkpoint 
G2/M 
checkpoint 
G1 
S G2 
M 
G2/M arrested cell 
!IL-6 
!IL-8 
!Wnt16B 
!GROα 
 
cdk4 cdk6 
Cyclin D 
INK CDK inhibitors 
e.g p16INK4a 
- 
- 
DNA Damage 
Cell stress 
Renal tubular 
epithelial cells 
p16INK4a+ve senescent cell 
!CTGF 
!TGF-β1 
 
DNA damage 
Chronic mitogenic stimuli 
Telomere erosion 
	 42	
Figure 4 - Age related pathways contributing to altered renal outcomes 
in the elderly  
Multiple pathways interact to produce the changes of renal aging and ↓GFR.  
Black text indicates implicated upstream effectors of aging, whilst red text 
reports the functional and histological changes found in the aged kidney 
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Figure 5 - Potential pathways and therapeutic targets for the treatment 
of renal aging  
Proposed aging associated pathways (left side), and potential interventions to 
address these, coded by current use in patients (green), experimental use in 
models of renal disease/aging (orange) or potential for future study in the	
kidney (red). 	
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Table 1 - Studies of putative aging pathways in vitro, in vivo and in man 
Changes in activity of various signalling pathways and mechanisms implicated 
in the response of kidney to increasing age.  Column 1 indicates cellular 
changes observed in vitro, column 2 reports effects seen in experimental 
models of renal aging and injury, and column 3 shows any reported effects in 
human aging and renal disease. 
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Aging factor In vitro studies Experimental studies Human studies 
Telomere 
shortening 
Shown in cells to reduce 
with length of passage.  
Critical shortening leads to 
senescence106. 
Reduced in mice with age108.  
Impaired regeneration after 
IRI109 
Reduced with age, with 
oxidative stress, CKD 
and HD150,152.  Risk 
factor for CVD151. 
Klotho 
signaling 
Klotho opposes signaling 
of IGF-1 and insulin43 in cell 
lines in vitro. 
Klotho deficiency decreases 
lifespan.45 Overexpression 
reduces IGF-1 and Wnt 
signaling and increases 
lifespan43 
Reduced with age132.  
Reduction associated 
with calcification and 
vascular disease136  
Wnt 
signaling 
Promotes profibrotic genes 
e.g. Snail, PAI1, MMP752.  
Levels increase with injury 
and in response to falling 
Klotho with aging53.  
Mediates renal RAAS 
signalling58 
Increases seen in CKD 
& linked to organ 
fibrosis197 
PPARγ 
levels 
Reduces oxidative 
stress/senescence in 
human fibroblasts64 
Reduced activity with age59,60.  
Agonists reduce renal 
inflammation/injury65 
Studies of PPARγ 
agonists suggest 
reduction in rates of 
proteinuria in 
diabetics138 
Antioxidant 
capacity 
 Aged rats have reduced renal 
antioxidant capacity, and 
enhanced renal injury79.  
Reduced oxidative stress 
lessens renal injury198 
Higher levels of 
oxidative stress in 
human aging and in 
CKD74. AGE 
accumulates with 
age142. 
Fibrosis ATII promotes fibrosis of 
glomerular cells and 
promotes reduction of 
SIRT-390 
Collagen I, III and TGF-β 
upregulated in aging mice51 
and rats66.  G2/M arrest is 
implicated in post injury 
renal fibrosis93. 
Nephrosclerosis a 
feature of aging and of 
hypertensive renal 
disease11,12.  Fibrosis 
and ATII 
hypersensitivity seen 
in aged kidneys141 
Senescence/ 
G1 Arrest 
Human and animal cells 
undergo senescence in 
vitro in response to stress 
or prolonged culture.95  
p16INK4a KO epithelial 
cells convert to 
mesenchyme more 
readily102 
p16INK4a and SA-beta-gal 
are markers for senescent 
cells and increased in aged 
animals and post-injury. 
G2/M arrest seen in scarred 
kidneys in response to 
injury93.    
Increased numbers of 
senescent renal cells 
correlate with 
increased injury and 
reduced transplant 
function146,147. 
Vascular 
changes 
Aged mice aortas have 
increased G2/M phase cell 
cycle arrest in vitro199 
Reduced renal capillary 
density in aged mice125  & in 
response to severe IRI115  
Increased renal 
vascular tone and 
vascular stiffening with 
age200. Loss of efficacy 
of vasodilators201  
Pericyte 
behavior 
Pericytes (but not 
myofibroblasts) stabilize 
endothelial cell cultures in 
vitro174  
Reduction of interstitial 
pericytes with aging125.  
Increased myofibroblasts in 
response to UUO and IRI 
injury202 
Comparative studies in 
aged humans (±CKD) 
have not been 
undertaken 
